In conclusion, our study provides new insights into the early immune response to breakthrough infection in patients with COVID‐19, highlighting different IgG and IgM antibody titers among patients with different intervals from receiving the second dose of inactivated vaccine to the onset of illness. The gene discussed is CD40LG; the disease is COVID-19.